A Brief Contact with Early Embryonic Cells Induces the Differentiation of Embryonal Carcinoma Cells: (embryonal carcinoma/differentiation/mouse embryo/aggregation chimera).

An assay system was developed to detect a switch of mouse embryonal carcinoma (EC) cells to the pathway for normal cell differentiation after a brief contact with normal embryonic cells. The system consisted of (1) the mixed aggregation of AT805 EC cells with 8-cell stage mouse embryos, (2) the stationary culture of the mixed aggregates into blastocysts and (3) the cell culture of inner cell masses isolated from chimeric blastocysts containing EC cells at 2, 3 and 4 days after the initiaion of chimeric aggregation. The number of foci of EC cells which appeared in the cultures of inner cell masses was decreased with a length of contact of EC cells with normal embryos as the mixed aggregates. After 4 days' contact, only fibroblastic and epithelial cells appeared in most cultures of inner cell masses. Examination of isozyme markers of GPI revealed that such cell cultures consisting of nonmalignant cells contained cells of tumor origin. Thus, it was concluded that a brief exposure to the environment of normal embryos can regulate the tumor cells to differentiate into non-malignant cells. This conclusion was substantiated by comparing the pattern of protein spots of the tumor cells with that of non-malignant cells of the tumor origin by two dimensional gel electrophoresis.

Conditional overexpression of transgenes in megakaryocytes and platelets in vivo.

Megakaryocyte (MK)-specific transgene expression has proved valuable in studying thrombotic and hemostatic processes. Constitutive expression of genes, however, could result in altered phenotypes due to compensatory mechanisms or lethality. To circumvent these limitations, we used the tetracycline/doxycycline (Tet)-off system to conditionally over-express genes in megakaryocytes and platelets in vivo. We generated 3 transactivator transgenic lines expressing the Tet transactivator element (tTA), under the control of the MK-specific platelet factor 4 promoter (PF4-tTA-VP16). Responder lines were simultaneously generated, each with a bidirectional minimal cytomegalovirus (CMV)-tTA responsive promoter driving prokaryotic beta-galactosidase gene, as a cellular reporter, and a gene of interest (in this case, the mitotic regulator Aurora-B). A transactivator founder line that strongly expressed PF4-driven tTA-viral protein 16 (VP16) was crossbred to a responder line. The homozygous double-transgenic mouse line exhibited doxycycline-dependent transgene overexpression in MKs and platelets. Using this line, platelets were conveniently indicated at sites of induced stress by beta-galactosidase staining. In addition, we confirmed our earlier report on effects of constitutive expression of Aurora-B, indicating a tight regulation at protein level and a modest effect on MK ploidy. Hence, we generated a new line, PF4-tTA-VP16, that is available for conditionally overexpressing genes of interest in the MK/platelet lineage in vivo.

Contribution of the hormone-response elements of the proximal ApoA-I promoter, ApoCIII enhancer, and C/EBP binding site of the proximal ApoA-I promoter to the hepatic and intestinal expression of the ApoA-I and ApoCIII genes in transgenic mice.

We have generated and studied the pattern of expression of transgenic mouse lines carrying the human apoA-I and apoCIII gene cluster mutated at different sites. In two lines, we have either mutated the hormone-response element (HRE) of element G of the apoCIII enhancer or the C/EBP binding site of the proximal apoA-I promoter. In a third line, we have mutated the two HREs of the apoA-I promoter and the HRE of the apoCIII enhancer. Mutations in the HRE of element G reduced the hepatic and intestinal expressions of the reporter chloramphenicol acetyltransferase (CAT) gene (which substituted the apoCIII gene) to 4 and 13% of the wild-type (WT) control, whereas the hepatic and intestinal expressions of the apoA-I gene were reduced to 92 and 25% of the WT control, respectively. A mutation in the C/EBP site increased the hepatic and intestinal expressions of the apoA-I gene approximately 1.25- and 1.6-fold, respectively, and did not affect the expression of the CAT gene. The mutation in the three HNF-4 binding sites of the apoA-I promoter/apoCIII enhancer nearly abolished the expression of apoA-I and the reporter CAT gene in all tissues. These findings establish the importance of the HREs for the hepatic and intestinal expressions of the apoA-I and apoCIII genes and suggest that C/EBP does not play a central role in the expression of the apoA-I gene.